

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Microablative Fractional Radiofrequency on vaginal health, microbiota, and cellularity of postmenopausal women: protocol of randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046372
Article Type:	Protocol
Date Submitted by the Author:	31-Oct-2020
Complete List of Authors:	Sarmiento, Ayane Cristine ; Universidade Federal do Rio Grande do Norte Fernandes, Fabíola; Universidade Federal do Rio Grande do Norte Costa, Ana Paula; Universidade Federal do Rio Grande do Norte Medeiros, Kleyton ; Universidade Federal do Rio Grande do Norte Crispim, Janaina; Universidade Federal do Rio Grande do Norte Gonçalves, Ana; Universidade Federal do Rio Grande do Norte
Keywords:	GYNAECOLOGY, Minimally invasive surgery < GYNAECOLOGY, Urogynaecology < GYNAECOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Microablative Fractional Radiofrequency on vaginal health, microbiota, and**
4 **cellularity of postmenopausal women: protocol of randomized controlled**
5 **trial**
6
7
8
9

10
11 Ayane Cristine Alves Sarmiento¹, Fabíola Sephora Fernandes², Ana Paula Ferreira
12 Costa¹, Kleyton Medeiros¹, Janaina C. Crispim², Ana Katherine Gonçalves^{1,3*}

13
14
15 ¹ Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte
16 (UFRN), Natal, RN, Brazil. E-mail: ayane_cris@hotmail.com / ana-paula-
17 rf@hotmail.com / kleyton_medeiros@hotmail.com

18
19
20
21 ² Department of Clinical Analysis and Toxicology, Federal University of Rio Grande
22 do Norte, Natal, Brazil. E-mail: fabiolasbp@gmail.com / janacrispimfre@gmail.com

23
24
25 ³ Department of obstetrics and gynaecology, Federal University of Rio Grande do
26 Norte (UFRN), Natal, RN, Brazil. E-mail: anakatherine_ufrnet@yahoo.com.br

27
28
29
30
31
32 *Correspondence

33 Ana Katherine Gonçalves

34 Email: anakatherine_ufrnet@yahoo.com.br (AKG)

35
36 ORCID ID: <https://orcid.org/0000-0002-8351-5119>

37
38
39
40
41 **Word count: 2.362**
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Menopause is a physiological and progressive phenomenon, secondary to decreased ovarian follicular reserve. These changes have as functional consequences: vaginal dryness, dyspareunia, sensations of discomfort, burning and irritation, vulvovaginal pruritus, dysuria, and increased frequency of genitourinary infections. The therapy more suitable for vaginal symptoms in post menopause yet is the use of topical hormone, once promote the renovation of the epithelium and vaginal flora, also improves the vulvovaginal atrophy symptoms. However, the prescription of topical estrogens should also be avoided in women with a history of breast cancer, estrogen-sensitive tumors, and thromboembolism, and this emphasizes the necessity for alternatives of treatment. Recently, physical methods, such as laser and radiofrequency (RF), in their non-ablative, ablative, and micro-ablative forms, have been used in the vaginal mucosa to promote neocolagenesis and ne elastogenesis. The objective of this randomized study is to compare the efficiency of microablative fractional radiofrequency (MAFRF) treatment with vaginal estrogens as well as no treatment.

Methods and analyses: This is a protocol of randomized, controlled clinical intervention trial with an open-label design comparing treatment of MAFRF, with vaginal estrogens as well as no treatment. Four important moments were considered for the evaluation of treatment results (T0, T1, T2, and T3). The primary endpoints will be vaginal microbiota, vaginal pH, and cell maturation. Secondary outcomes include the Vaginal Health Index (VHI), which will be applied only at times T0 and T3.

Ethics and dissemination: Due to the nature of the study, we obtained approval from the Ethics Committee. All participants must sign an informed consent form before randomization. The results of this study will be published in peer-reviewed journals. The data collected will also be available in a public repository of data.

Trial registration number: UTN - U1111-1212-5960

Keywords: Menopause; Radiofrequency; Laser; Lactobacillus; Therapeutics.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- To the authors' knowledge, this is the first pilot randomized controlled trial (RCT) comparing the effect of Microablative Fractional Radiofrequency (MAFRF) with vaginal estrogens as well as no treatment for this patient population.
- Findings are likely to be clinically relevant and useful for treating postmenopausal women with a history of breast cancer, estrogen-sensitive tumors.
- Our strict inclusion criteria for participants will increase the likelihood of a more homogeneous postmenopausal women group and reduce selection bias.
- Blinding of participants, blinding of assessors of outcomes, detailed standardization of treatment protocols, and rigorous training for the researchers enhance this trial's internal validity.
- The study of postmenopausal women, and therefore its results may not be generalizable to other populations.
- This is a study of postmenopausal women, and therefore its results may not be generalizable to other populations.

INTRODUCTION

Menopause is a physiological and progressive phenomenon, secondary to decreased ovarian follicular reserve. Estrogen deficiency is responsible for the mucosa vulvovaginal thinning of the squamous epithelium, a decrease in the number of collagen and elastin fibers, impaired cell function, reduction in the number of vessel changes in vaginal pH, and in flora commensal.[1]

These changes have functional consequences, being vaginal dryness, dyspareunia, sensations of discomfort, burning and irritation, vulvovaginal pruritus, dysuria, and increased frequency of genitourinary infections.[1] The term Genitourinary Syndrome in Menopause (GSM) was defined in 2014 at a North American consensus conference, where all the disabling symptoms of the urogenital sphere secondary to menopause were more fully and objectively identified.[2]

The therapy more suitable for vaginal symptoms in post menopause yet is the use of the topical hormone, once promote the renovation of the epithelium and vaginal flora, also improves the vulvovaginal atrophy symptoms (VVA).[3] Besides that, the use of low-dose vaginal estrogen has demonstrated to be superior to systemic therapy for improvement VVA.[4] However, a major limitation is associated with low adherence to treatment, due to multiple and inconvenient self-applications and increased vaginal discharge. We cannot fail to emphasize that the prescription of topical estrogens should be avoided in women with a history of breast cancer, estrogen-sensitive tumors, and thromboembolism. For these reasons are necessary to search for alternatives to treatment.[5]

The use of fractional micro ablative CO2 laser therapy was approved in 2014, the Food and Drug Administration (FDA), but only for genitourinary surgery. Considering the context of the treatment of GSM, in order to avoid hormonal

1
2
3 interventions, the micro-ablative fractional CO2 laser, or the non-ablative vaginal
4 erbium YAG laser can be considered. Beyond the laser, other non-ablative
5 electromagnetic energy, such as radiofrequency, are being considered for this
6
7
8
9
10 indication.[6]

11
12 Radiofrequency (RF) is a technique that involves cutting and coagulating
13 biological tissues by using a high-frequency alternating current, which instantly
14 raises the intracellular temperature to 100°C, thus determining cellular membrane
15 expansion and rupture. By reaching the frequency of 4,000,000 cycles/second
16 (4MHz), the FM radio frequency is obtained – this feature giving rise to the name
17 RF electro-surgery. Microablative fractional radiofrequency (MAFRF) is a new
18 procedure that uses random energy in a fractionation system that observes the
19 thermal relaxation of the tissue at a certain time. Energy fractionation consists of
20 energy distribution at equidistant points, producing microscopic columns of thermal
21 injuries in the epidermis and upper dermis, resulting in microscopic columns of
22 treated tissue and intervening areas of untreated skin, which in turn achieve faster
23 reepithelialization. [7,8]

24
25 We can consider that the current literature lacks still needs research
26 regarding the use of radiofrequency for the treatment of GSM, most publications
27 evaluate only use the laser. The few studies that have been done on radiofrequency,
28 are mostly restricted to results on sexual function and quality of life. There are no
29 results about the clinical evaluations as pH, cellularity, and vaginal flora when using
30 radio frequency, and that is exactly our proposal.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58 Objectives
59
60

1
2
3 We aim to investigate the therapeutic effect of vaginal MRFM in the
4 genitourinary symptoms of climacteric women. We postulate that MAFRF promotes
5 Cell Maturation by increasing superficial cells and decreasing parabasal cells.
6
7 Furthermore, we believe that it causes alteration of the microbiota vaginal, with an
8 increased number of vaginal lactobacilli, and decreases the vaginal pH. Thus, it is
9 possible to hypothesize that the MAFRF treatment is as safe and effective as
10 standard vaginal estrogen treatment.
11
12
13
14
15
16
17
18
19
20

21 **METHODS AND ANALYSIS**

22
23
24 This protocol will adhere to the Standard Protocol Items for Randomized
25 Trials (SPIRIT)[9] and CONSORT statements.[10]

26 27 28 Trial design

29
30 The study is a randomized protocol, controlled clinical intervention trial with
31 an open-label design comparing treatment with MAFRF with vaginal estrogens as
32 well as no treatment.
33
34
35
36
37
38
39

40 41 Population

42 Participant recruitment is currently ongoing at a gynecological Unit of a public
43 university hospital. Patients who fulfill the inclusion criteria and who sign the free
44 and informed consent forms will enter the screening period. Patients who meet the
45 exclusion criteria will be excluded before randomization.
46
47
48
49
50
51
52
53
54
55
56
57

58 59 Eligibility criteria and recruitment

60

1
2
3 The treatments will be conducted at one biggest gynecological unit of
4 a public university Hospital Brazil. Participants will be sought via referrals from
5 gynecologists physicians that attend in this hospital. The study will include healthy
6 postmenopausal women (55 to 65 years old, with whom at least 12 months have
7 passed since last menstrual period or bilateral oophorectomy), who are still sexually
8 active, with GSM, plasma gonadotropin and presenting serum estradiol levels in the
9 postmenopausal range (FSH >40 U/L; estradiol <25 pg/ml) as well as negative
10 Papanicolaou (Pap) smear for cervical cancer precursor cells. Women who have
11 used any form of hormonal (systemic or local) therapy in the last six months,
12 lubricants or vaginal moisturizers in the past month, suffering from active genital
13 infections and any disease that would interfere following the protocol will be
14 excluded. Figure1 shows the study flow.

Interventions

35 The microablative fractional radiofrequency (MAFRF) will be performed
36 according to the technique described by Kamilos and Borelli.[6] For the procedure,
37 the Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX
38 system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic
39 circuit of energy fractionation, connected to a vaginal pen with 64 microneedles,
40 200 μ in diameter and 1mm in length, mounted on a Teflon body and divided into an
41 eight-column matrix with eight needles each.[8]

51 In the vestibule and vaginal opening, 10% lidocaine spray will be applied 3
52 minutes before the procedure. Three applications will be realized in the
53 vagina/vaginal introitus, with intervals of 30 days. A sequential application will be
54 performed on the vaginal walls under direct vision. For the post-treatment care, the
55
56
57
58
59
60

1
2
3 use of 5% dexpanthenol solution in the vaginal opening will be recommended two
4
5 to three times a day, for 2 to 5 days. With no intercourse for ten days.[8] The
6
7 procedure will be performed in the outpatient clinic by an experienced gynecologist,
8
9 and a single gynecologist supervises the carrying out of the whole process for the
10
11 entire period of the research.
12
13

14 The patients from the group with estrogen will be instructed to use Estradiol
15
16 17 β -based vaginal cream, 1g corresponding to the use of the filled applicator up to
17
18 the ring mark, twice a week, for three months.[11-13]. The patients who did not
19
20 receive any intervention will be instructed to attend the consultation for follow-up
21
22 according to what was established in the study protocol.
23
24
25
26
27

28 Questionnaire

29
30 In the first query, the women will answer a standardized questionnaire with
31
32 information on demographic characteristics including age, time menopause, skin
33
34 color, schooling, and socioeconomic classification.
35
36
37
38
39

40 Outcomes

41
42 Four relevant time points were considered for the evaluation of treatment
43
44 results based on a previous study [8] baseline (T0), 30 days after the first application
45
46 (T1), 30 days after second application (T2), and 30 days after the third
47
48 radiofrequency application (T3). Primary outcomes were vaginal microbiota, vaginal
49
50 pH, and cell maturation. Primary outcomes will be vaginal microbiota, vaginal pH,
51
52 and cell maturation. Vaginal smears will be obtained, which will be subsequently
53
54 stained according to the standard Gram staining procedure for the classification of
55
56 vaginal flora, following the criteria of Spiegel.[14] Vaginal pH can be measured in
57
58
59
60

1
2
3 different ways. Most studies describe the use of a pH indicator stripe on the lateral
4 wall of the vagina.[15,16] Moreover, vaginal pH measurement is considered useful,
5 practical, and inexpensive. For vaginal pH determination, the pH indicator strips will
6 be applied against the vaginal wall. The pH will be measured by the gynecologist
7 responsible for the procedure. For analysis of vaginal cytology, vaginal smears will
8 be obtained from the upper third of the right lateral vaginal wall, at predefined times.
9
10 The material collected from the vaginal sac will be distributed on the blade,
11 adequately identified and fixed, and subsequently stained by the Papanicolaou
12 technique for determining the degree of maturation of the vaginal epithelium by the
13 Frost Index.[17,18]
14
15
16
17
18
19
20
21
22
23
24
25

26 The latter will be analyzed in the laboratory by two cytologists who are unaware of
27 the women's identity and at what times of treatment the samples were obtained.
28
29

30 Secondary outcomes include the Vaginal Health Index (VHI). The vaginal
31 health score consists of the clinical analysis during the specular examination of five
32 parameters (elasticity, fluid volume, pH, the integrity of the epithelium, and
33 humidity), and is graded from 1 to 5. The sum of the values of the parameters
34 evaluated results in the total vaginal health score. When the overall rating is less
35 than 15, the vaginal mucosa is considered atrophic.[19] The evaluation of the results
36 is described in Table 1.
37
38
39
40
41
42
43
44
45
46

47 All possible adverse effects will be recorded and qualified during the period
48 of treatment using questionnaires developed for this protocol. The adverse events
49 will be reported in the results section of the manuscript and will be discussed. Any
50 breaches of confidentiality, study protocol, or adverse events (AEs) attributable to
51 this study will be reported to the research ethics committees.
52
53
54
55
56
57
58
59
60

Table 1. Outcome measurements

Outcome measurements	Explanation	Time point for assessment
Characterization of the vaginal ecosystem by Spiegel criteria	Vaginal flora will be classified, after gram stain according to the Spiegel Criteria, into type 1 (predominance of at least 85% lactobacilli), type 2 (balance between 50% lactobacilli and coccoid flora) and type 3 (0%, almost complete absence of lactobacilli with the presence of cocoidal flora).[14]	T0, T1, T2, and T3
Determination of vaginal pH	The vaginal pH values will be obtained with the application of a universal pH tape 4-7, produced by Merck (MColorpHast™, Merck, Germany), directly on the right lateral vaginal wall at the allotted times. A pH less than or equal to 5.0 would be indicative of normal vaginal trophism and a pH greater than 5 would be indicative of vaginal atrophy.[1]	T0, T1, T2, and T3
Vaginal maturation	The slides will be examined by light microscopy, using a 10-magnification eyepiece and a 10X objective for the initial evaluation. Then, 100 cells will be analyzed with the same 40X objective and eyepiece in 5 randomly chosen fields. The percentage count of each cell type will be made, that is, parabasal, intermediate, and superficial cells (P / I / S), obtaining the cell maturation index or Frost index.[18] The maturation of the	T0, T1, T2, and T3

	vaginal epithelium (positive effect of the treatment) is evidenced by a decrease in parabasal cells and an increase in the proportion of superficial cells.[19]	
Vaginal Health Index (VHI)	VHI scores of vaginal moisture, vaginal fluid volume, vaginal elasticity, pH, and vaginal epithelial integrity on a scale of 1 (most inferior) to 5 (best) will be found. Vaginal moisture is an assessment of the appearance or consistency of the secretions that line the vagina. Vaginal elasticity is a measurement of the vaginal tissue's ability to stretch at the examiner's touch. Epithelial integrity takes into account color, thickness, and the absence of vaginal bleeding. The lower the score, the higher the atrophy.[4] The sum of the values of the evaluated parameters results in the total vaginal health score. When the overall score is less than 15, the vaginal mucosa is considered atrophic.[15]	T0 and T3

Follow-up

Data will be recorded during the follow-up period according to the multiple time points. The details are shown in Table 2.

Period 1: Screening time (day 0): before treatment.

Period 2: Intervention time (T1-T3): data will be recorded every seven days and 30 days during follow-up.

Period 3: The time after the intervention (within one year after treatment): follow-up at one year for long-term results.

Table 2. Schedule of enrollment, interventions, assessments and data collection

	Study Period				
	Enrollment / Baseline	Intervention			Follow-up
Time point	T0	T1	T2	T3	1 YEAR
Enrollment:	X				
Eligibility screen	X				
Informed consent	X				
Randomization	X				
Interventions:					
MAFRF		X	X	X	
vaginal estrogens		X	X	X	
no treatment		X	X	X	
Assessments:					
General condition					X

Sample size

Therefore, with an equal 1:1:1 allocation rate, according to the results of a pilot study, where data came from 55 volunteers,[20] accepting an alpha of 0.05 and a beta risk <0.2 in a bilateral contrast, assuming a patient attrition rate at follow-up of approximately 15%–20%. The total sample size needed will be established at patients 198, 66 in each group (66 in the MAFRF group, 66 in with vaginal estrogens, and 66 in the as no treatment).

Randomization and allocation concealment

Eligible participants who provide written consent will be randomized into the Software Research Randomizer® programme. Randomization will be by block (1:1:1). Patients will be randomized into three intervention groups (MAFRF group, vaginal estrogens group, and no treatment group). In order to ensure allocation concealment, an offsite randomization schedule will be used. The randomization schedule will be prepared in advance by a researcher at the Federal University of Rio Grande do Norte (UFRN), who will have no contact with any participants throughout the trial and will not be involved in the recruitment, screening, assessment, enrollment or treatment process. To enroll a participant, the primary researcher will email the consenting participant's name to the researcher at the Federal University of Rio Grande do Norte (UFRN). These details will be entered into the allocation spreadsheet, and the next treatment allocation and participant identification number will be emailed directly to the treatment.

Blinding

Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group.

Data management

Researchers qualified are crucial that ensure the quality of a clinical trial. The researchers should understand the specific contents of the protocol. Data collection will be performed by experienced staff using an online electronic data system. The quality of the data management will be checked by the reliability, controlled access, and traceability of the system. Data management will include baseline characteristics (demographics, comorbidities, inclusion and exclusion criteria, and

1
2
3 blood test), potential confounder, and outcomes. Participants who withdraw from
4
5 our study for any reason will be followed up, and data will be analyzed according to
6
7 the intention-to-treat (ITT) principle. All randomized participants will be followed up
8
9 until one year after randomization.
10
11
12
13

14 Data extraction and statistical analysis

15
16
17 Data will be analyzed on an intention-to-treat basis, including all participants
18
19 enrolled in each group. Epidemiological and clinical characteristics data will be
20
21 analyzed using the chi-squared test, nonparametric Kruskal–Wallis test, and
22
23 analysis of variance. Analysis of percentages in each group (MAFRF, and no
24
25 treatment) compared with the control group (vaginal estrogens), for vaginal
26
27 maturation index, pH, vaginal health, and presence of lactobacilli will be performed
28
29 with the chi-squared and Fisher’s exact tests. $P < 0.05$ will be considered statistically
30
31 significant. The software that will be used is SPSS for Windows, version 20.0 (IBM
32
33 Corp., Armonk, NY, USA).
34
35
36
37
38
39

40 Patient and public involvement

41
42 Neither patients nor public were involved in the development of the research
43
44 question, study design, outcome measures, recruitment to and conduct of the study
45
46 or assessment of the burden of the intervention. The results of the study will be
47
48 disseminated to study participants by means of lectures given by the investigators.
49
50
51
52

53 DISCUSSION

54
55
56 In this protocol, we described our randomized trial comparing the MAFRF to
57
58 estrogen vaginal and placebo in order to evaluate radiofrequency as a new
59
60

1
2
3 treatment option for GSM. The strengths of this trial are the randomized design that
4 allows control, by chance, of confounding factors, ease in forming the control group,
5 and ability for the analysis of several clinical outcomes simultaneously. The main
6 limitation is the loss of follow-up that occurs due to the extended treatment period.
7
8
9

10
11
12 It is recognized that vaginal estrogen may improve the symptoms of GSM,
13 on the other hand, the non-hormonal approach can be useful in specific cases in
14 which hormonal treatment is feared or not recommended (for instance, when there
15 is breast cancer).[21,22] Although the laser is the most well-known and used
16 physical method, using radiofrequency presents advantages, such as the
17 application is realized under direct vision, and there is the use of a vaginal speculum,
18 facilitating treatment along the vaginal walls and preventing overlapping of shots.
19 As well as this, the method is easy to learn and less costly. The procedure features
20 a useful tolerance index, the patients recovered quickly, and the microablation
21 disappeared 3 to 5 days after the application.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **ETHICS AND DISSEMINATION**

38
39
40 All the procedures performed in this study involving human participants will be
41 conducted in accordance with the ethical standards of the 1964 Declaration of
42 Helsinki and its later amendments, the Declaration of Madrid of the World
43 Psychiatric Association and the established requirements for manuscripts submitted
44 to biomedical journals or comparable ethical standards of good clinical practice. The
45 trial was approved by the local Division Ethics Committee (date of approval: April
46 17, 2018; reference number: 81973618.2.0000.5292) and was registered in the
47 Brazilian Clinical Trials Registry (ReBec) - (number registry UTN - U1111-1212-
48
49
50
51
52
53
54
55
56
57
58
59
60

5960) before enrollment of trial participants. Patients confidentiality will be assured through data anonymization.

REFERENCES

1. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause* 2013;20(9):888–902.
2. Portman DJ, Gass MLS. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. *Maturitas* 2014;79(3):349–54.
3. Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. *Am J Obstet Gynecol* 2016;215:704-711.
4. Tzur T, Yohai D, Weintraub AY. The role of local estrogen therapy in the management of pelvic floor disorders. *Climacteric* 2016;19:162-171.
5. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 2016;8:CD001500.
6. Vicariotto F, DE Seta F, Faoro V, et al. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvovaginal atrophy: 12-month efficacy and safety. *Minerva Ginecol* 2017;69:342-349.
7. Casabona G, Presti C, Manzini M, et al. Fractional ablative radiofrequency: a pilot study with twenty cases involving rejuvenation of the lower eyelid. *Surg Cosmet Dermatol* 2014;6(1):50-5.

- 1
2
3 8. Kamilos MF, Borelli CL. New therapeutic option in genitourinary syndrome
4 of menopause: pilot study using microablative fractional radiofrequency.
5
6 *Einstein* 2017;(15):445-51.
7
8
- 9
10 9. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
11 SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
12 trials. *BMJ* 2013;346:e7586.
13
14
- 15
16 10. Schulz KF, Altman DG, Moher D. CONSORT 2010: updated guidelines for
17 reporting parallel group randomised trials. *Ann Intern Med* 2010;152:1–8.
18
19
- 20
21 11. Constantine GD, Simon JA, Pickar JH, et al; REJOICE Study Group. The
22 REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety
23 and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic
24 vulvar and vaginal atrophy. *Menopause* 2017;24(4):409-416.
25
26
- 27
28 12. Simon JA, Archer DF, Constantine GD, et al. A vaginal estradiol softgel
29 capsule, TX-004HR, has negligible to very low systemic absorption of
30 estradiol: efficacy and pharmacokinetic data review. *Maturitas* 2017;99:51-
31 58.
32
33
- 34
35 13. Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause:
36 Management Strategies for the Clinician. *Mayo Clin Proc* 2017;92(12):1842-
37 1849.
38
39
- 40
41 14. Spiegel CA, Amsel LR. Diagnosis of bacterial vaginosis by direct gram stain
42 of vaginal fluid. *J. Clin Microbiol* 1983;18:170-72.
43
44
- 45
46 15. Lee YK, Chung HH, Kim JW, et al. Vaginal pH balanced gel for the control
47 of atrophic vaginitis among breast cancer survivors: a randomized controlled
48 trial. *Obstet Gynecol* 2011;117(4):922-927.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 16. Ekin M, Yasar L, Savan K, et al. The comparison of hyaluronic acid vaginal
4 tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a
5 randomized controlled trial. *Arch Gynecol Obstet* 2011;283(3):539-543.
6
7
8
9
10 17. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic
11 vaginitis. *Am Fam Physician*. 2000;61(10):3090-6.
12
13
14 18. Lencioni LJ. *Citologia endócrina*. 1ª ed. Buenos Aires: *Médica Pan*
15 *Americana* 1987.
16
17
18
19 19. Lustosa AB, Girão MJBC, Sartori MGF, et al. Urinary and Vaginal Cytology
20 of Postmenopausal Women with Oral and Transdermal Estrogen
21 Replacement. *RBGO* 2002; 24, (9):573-577.
22
23
24
25 20. Sarmiento AC, Fernandes FS, Marconi C, et al. Impact of microablative
26 fractional radiofrequency on the vaginal health, microbiota, and cellularity o
27 postmenopausal women. *CLINICS* 2020;75:1750.
28
29
30
31
32 21. Davis SR. Understanding female sexual function. *Menopause* 16. 2009;(3):425–
33 6, doi:10.1097/gme.0b013e31819c67a7.
34
35
36
37 22. Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in
38 postmenopausal women: findings from the REVIVE (Real Women’s Views
39 of Treatment Options for Menopausal Vaginal Changes) survey. *The J. Sex.*
40 *Med* 2013;10(7):1790-1799. doi: 10.1111/jsm.12190.
41
42
43
44
45
46
47
48

49 **Authors’ contributions:** ACAS, AKG were involved in drafting the study protocol.
50
51 KM and APFC were involved in statistical planning and drafting of the study protocol.
52
53 JCC and FSF was involved in drafting and revising the study protocol. AKG
54 developed the idea for this trial and was involved in drafting and revising the study
55 protocol. ACAS conceived and developed the idea for this trial, was involved in
56
57
58
59
60

1
2
3 drafting and revising the study protocol and was the principal investigator of this trial.

4
5 All authors are involved in data acquisition and approved the final version of the
6
7 manuscript.
8
9

10 **Conflict of interest statement:** The authors report no conflict of interest.

11
12 **Funding:** This work was supported by Brazilian CNPq (National Council for
13 Scientific and Technological Development). Grant number 436740/2018-4.
14
15

16
17 **Disclaimer:** These funding sources have no role in the design of this study and will
18 not have any role during its execution, analyses, interpretation of the data, or
19 decision to submit results.
20
21
22

23
24 **Data sharing statement:** All investigators will maintain full autonomy and
25 involvement in the design, conduct and reporting of the trial with everyone having
26 full access to the final data.
27
28
29

30
31 **Confidentiality:** The original documents and files will be kept at the trial sites for
32 15 years. The lead investigator is responsible for data and file storage. The lead
33 investigator is responsible for data and files storage for 15 years.
34
35
36

37
38 **Consent or assent:** All participants will be asked to sign an informed consent form
39 to join the trial. The form explicitly contains all stages of research.
40
41

42
43 **Ethics approval:** The trial was approved by the local Division Ethics Committee
44 (date of approval: April 17, 2018; reference number: 81973618.2.0000.5292) and
45 registered in the Brazilian Clinical Trials Registry - ReBec: (number registry UTN -
46 U1111-1212-5960).
47
48
49
50

51
52
53
54
55
56 **Figure legend:**

57
58 **Figure 1. CONSORT 2010 Flow Diagram**
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. CONSORT 2010 Flow Diagram

239x309mm (96 x 96 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	01
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	01
	2b	All items from the World Health Organization Trial Registration Data Set	01
Protocol version	3	Date and version identifier	01
Funding	4	Sources and types of financial, material, and other support	01
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	01
	5b	Name and contact information for the trial sponsor	19
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	19
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	X

1	Introduction			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	04-05
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	05
7				
8	Objectives	7	Specific objectives or hypotheses	06
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	06
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	06
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	07
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	07-08
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	07
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	07-08
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	08
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	08-09
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
35			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	10-12
39			participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	12
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	13
5				
6				
7	Methods: Assignment of interventions (for controlled trials)			
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	13
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	13
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	13
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	13
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	14
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14-15
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	14-15
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	14
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	14-15
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	15
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	X
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	X
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	06
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	X
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	16
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	16
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	20
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	X
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	20
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	20
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	20
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	X
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	X
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	X
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	X
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	X
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	X
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.

BMJ Open

Microablative Fractional Radiofrequency on sexual function and vaginal health: protocol of a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046372.R1
Article Type:	Protocol
Date Submitted by the Author:	17-May-2021
Complete List of Authors:	Sarmiento, Ayane Cristine ; Universidade Federal do Rio Grande do Norte Fernandes, Fabíola; Universidade Federal do Rio Grande do Norte Costa, Ana Paula; Universidade Federal do Rio Grande do Norte Medeiros, Kleyton ; Universidade Federal do Rio Grande do Norte Crispim, Janaina; Universidade Federal do Rio Grande do Norte Gonçalves, Ana; Universidade Federal do Rio Grande do Norte
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Sexual health, Medical management
Keywords:	GYNAECOLOGY, Sexual dysfunction < UROLOGY, SEXUAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Microablative Fractional Radiofrequency on sexual function and vaginal**
4 **health: protocol of a randomized controlled trial**
5
6

7 Ayane Cristine Alves Sarmiento¹, Fabíola Sephora Fernandes², Ana Paula Ferreira
8 Costa¹, Kleyton Santos Medeiros¹, Janaina C. Crispim², Ana Katherine
9 Gonçalves^{1,3*}
10
11

12
13 ¹ Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte
14 (UFRN), Natal, RN, Brazil. E-mail: ayane_cris@hotmail.com / [ana-paula-
16 rf@hotmail.com](mailto:ana-paula-
15 rf@hotmail.com) / kleyton_medeiros@hotmail.com
17

18
19 ² Department of Clinical Analysis and Toxicology, Federal University of Rio Grande
20 do Norte, Natal, Brazil. E-mail: fabiolasbp@gmail.com / janacrispimfre@gmail.com
21
22

23 ³ Department of obstetrics and gynaecology, Federal University of Rio Grande do
24 Norte (UFRN), Natal, RN, Brazil. E-mail: anakatherine_ufrnet@yahoo.com.br
25
26

27
28
29 *Correspondence

30 Ana Katherine Gonçalves

31 Email: anakatherine_ufrnet@yahoo.com.br (AKG)

32 ORCID ID: <https://orcid.org/0000-0002-8351-5119>
33
34
35
36
37
38

39 **Word count: 3.004**
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve. These changes have consequences: vaginal dryness, dyspareunia, discomfort, burning and irritation, vulvovaginal pruritus, dysuria, and increased frequency of genitourinary infections. The therapy more suitable for vaginal symptoms in post-menopause yet is the use of a topical hormone. However, the prescription of topical estrogens should also be avoided in women with a history of breast cancer, estrogen-sensitive tumors, and thromboembolism, emphasizing the necessity of alternative treatments. Recently, physical methods, such as laser and radiofrequency (RF), in their non-ablative, ablative, and micro-ablative forms, have been used in the vaginal mucosa to promote neocolagenesis and neolastogenesis. This randomized study aims to compare the efficiency of Microablative Fractional Radiofrequency (MAFRF) treatment with vaginal estrogens and no treatment.

Methods and analyses: This randomized, controlled clinical intervention trial with an open-label design comparing the treatment of MAFRF with vaginal estrogens and no treatment. Four important moments were considered to evaluate treatment results (T0, T1, T2, and T3). The primary outcomes include the female sexual function and the secondary outcome will be vaginal health that will be evaluated per Vaginal Health Index (epithelial integrity, vaginal elasticity, moisture, fluid volume, and pH vaginal), beyond the vaginal microbiota, and cell maturation.

Ethics and dissemination: Due to the nature of the study, we obtained approval from the Ethics Committee. All participants must sign an informed consent form before randomization. The results of this study will be published in peer-reviewed journals. The data collected will also be available in a public repository of data.

Trial registration number: Registered in REBEC (Brazilian Registry of Clinical Trials) under number RBR-94DX93. This study was approved by the Division Ethics Committee of University Hospital Onofre Lopes (UFRN), under CAAE 81973618.2.0000.5292.

Keywords: Menopause; Radiofrequency; Laser; Lactobacillus; Therapeutics.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The latter is the first randomized controlled trial comparing the MAFRF with the golden standard (vaginal estrogen).
- Inclusion criteria allow homogeneity of subjects and less risk of bias.
- Blinding of assessors and standardization of protocols enhance this trial's internal validity.
- The study will be performed among postmenopausal women; thus, its results may not be generalizable to other populations.

INTRODUCTION

Menopause is a physiological and progressive phenomenon, secondary to decreased ovarian follicular reserve. Estrogen deficiency is responsible for the mucosa vulvovaginal thinning of the squamous epithelium, a decrease in the number of collagen and elastin fibers, impaired cell function, reduction in the number of vessel changes in vaginal pH, and in flora commensal.[1]

These changes have functional consequences, being vaginal dryness, dyspareunia, sensations of discomfort, burning and irritation, vulvovaginal pruritus, dysuria, and increased frequency of genitourinary infections.[1] The term Genitourinary Syndrome of Menopause (GSM) was defined in 2014 at a North American consensus conference, where all the disabling symptoms of the urogenital sphere secondary to menopause were more fully and objectively identified.[2]

The therapy more suitable for vaginal symptoms in post menopause yet is the use of the topical hormone, once promote the renovation of the epithelium and vaginal flora, also improves the vulvovaginal atrophy symptoms (VVA).[3] Besides that, the use of low-dose vaginal estrogen has demonstrated to be superior to systemic therapy for improvement VVA.[4] However, a major limitation is associated with low adherence to treatment, due to multiple and inconvenient self-applications and increased vaginal discharge. We cannot fail to emphasize that the prescription of topical estrogens should be avoided in women with a history of breast cancer, estrogen-sensitive tumors, and thromboembolism. For these reasons are necessary to search for alternatives to treatment.[5]

The use of fractional micro ablative CO2 laser therapy was approved in 2014, the Food and Drug Administration (FDA), but only for genitourinary surgery. Considering the context of the treatment of GSM, in order to avoid hormonal

1
2
3 interventions, the micro-ablative fractional CO₂ laser, or the non-ablative vaginal
4 erbium YAG laser can be considered. Recently, studies showed that the use of
5 fractional CO₂ laser in the treatment of VVA was beneficial, effective, and safe. The
6 latter positive effects on VVA symptoms can be improved not only the quality of life;
7 but also the aspect of sexual pain; and other dimensions of women's sexual
8 response, such as desire, initiative, and receptivity to their sexual partner.[6-8]
9
10 Similar results have been observed in the use of YAG laser treatment. Application
11 of Er: YAG laser is associated with an improvement in vaginal atrophy, and such
12 treatment induced a significant decrease in Visual Analog Scale (VAS), an increase
13 of VHI, and a significant improvement in urinary incontinence.[9,10] Beyond the
14 laser, other non-ablative electromagnetic energy, such as radiofrequency, are being
15 considered for this indication.[11]

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 Radiofrequency (RF) is a technique that involves cutting and coagulating
32 biological tissues by using a high-frequency alternating current, which instantly
33 raises the intracellular temperature to 100°C, thus determining cellular membrane
34 expansion and rupture. By reaching the frequency of 4,000,000 cycles/second
35 (4MHz), the FM radio frequency is obtained – this feature giving rise to the name
36 RF electrosurgery. Microablative fractional radiofrequency (MAFRF) is a new
37 procedure that uses random energy in a fractionation system that observes the
38 thermal relaxation of the tissue at a certain time. Energy fractionation consists of
39 energy distribution at equidistant points, producing microscopic columns of thermal
40 injuries in the epidermis and upper dermis, resulting in microscopic columns of
41 treated tissue and intervening areas of untreated skin, which in turn achieve faster
42 reepithelialization.[12,13]
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We can consider that the current literature lacks still needs research
4 regarding the use of radiofrequency for the treatment of GSM, most publications
5 evaluate only use the laser. The few studies that have been done on radiofrequency,
6
7 are mostly restricted to results on sexual function and quality of life. There are no
8 results about the clinical evaluations as pH, cellularity, and vaginal flora when using
9 radio frequency, and that is exactly our proposal.
10
11
12
13
14
15
16
17
18

19 Objectives

20
21 We aim to investigate the therapeutic effect of vaginal MARFM in the
22 genitourinary symptoms of climacteric women. We postulate that MAFRF could
23 promote the improvement of sexual function and vaginal health. Furthermore, could
24 occur cell maturation based on increasing superficial cells and decreasing parabasal
25 cells. Additionally, could appear alteration of the microbiota vaginal, with an
26 increased number of vaginal lactobacilli, and decreases the vaginal pH. Thus, it is
27 possible to hypothesize that the MAFRF treatment is as safe and effective as
28 standard vaginal estrogen treatment.
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **METHODS AND ANALYSIS**

43
44 This protocol will adhere to the Standard Protocol Items for Randomized
45 Trials (SPIRIT)[14] and CONSORT statements.[15]
46
47
48
49
50

51 Trial design

52
53 The study is a randomized protocol, controlled clinical intervention trial with
54 a single-blind design comparing treatment with MAFRF with vaginal estrogens as
55 well as no treatment.
56
57
58
59
60

Population

Participant recruitment is currently ongoing at a gynecological Unit of a public university hospital. Patients who fulfill the inclusion criteria and who sign the free and informed consent forms will enter the screening period. Patients who meet the exclusion criteria will be excluded before randomization.

Eligibility criteria and recruitment

The treatments will be conducted at one biggest gynecological unit of a public university Hospital Brazil. Participants will be sought via referrals from gynecologists physicians that attend in this hospital. The study will include healthy postmenopausal women (55 to 65 years old, with whom at least 12 months have passed since last menstrual period or bilateral oophorectomy), who are still sexually active, with GSM, plasma gonadotropin and presenting serum estradiol levels in the postmenopausal range (FSH >40 U/L; estradiol <25 pg/ml) as well as negative Papanicolaou (Pap) smear for cervical cancer precursor cells. Women who have used any form of hormonal (systemic or local) therapy in the last six months, lubricants or vaginal moisturizers in the past month, suffering from active genital infections (diagnosis by GRAM stain and Multiplex-PCR), and any disease that would interfere following the protocol will be excluded. Figure 1 shows the study flow.

Interventions

The microablative fractional radiofrequency (MAFRF) will be performed according to the technique described by Kamilos and Borelli.[13] for the procedure, the Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic

1
2
3 circuit of energy fractionation, connected to a vaginal pen with 64 microneedles,
4
5 200 μ in diameter and 1mm in length, mounted on a Teflon body and divided into an
6
7 eight-column matrix with eight needles each.[13]
8
9

10 In the vestibule and vaginal opening, 10% lidocaine spray will be applied 3
11
12 minutes before the procedure. Three applications will be realized in the
13
14 vagina/vaginal introitus, with intervals of 30 days. A sequential application will be
15
16 performed on the vaginal walls under direct vision. For the post-treatment care, the
17
18 use of 5% dexpanthenol solution in the vaginal opening will be recommended two
19
20 to three times a day, for 2 to 5 days. With no intercourse for ten days.[13] The
21
22 procedure will be performed in the outpatient clinic by an experienced gynecologist,
23
24 and a single gynecologist supervises the carrying out of the whole process for the
25
26 entire period of the research.
27
28
29

30 The patients from the group with estrogen will be instructed to use
31
32 Promestriene (Estradiol 3-propyl 17 β -methyl diether) vaginal cream, 1g
33
34 corresponding to the use of the filled applicator up to the ring mark, twice a week,
35
36 for three months.[16-18]
37
38
39

40 The patients who did not receive any intervention will be instructed to attend
41
42 the consultation for follow-up according to what was established in the study
43
44 protocol.
45
46
47
48

49 Questionnaire

50
51 In the first query, the women will answer a standardized questionnaire with
52
53 information on demographic characteristics including age, time menopause, skin
54
55 color, schooling, and socioeconomic classification.
56
57
58
59
60

Outcomes

Two relevant time points will be considered for evaluating female sexual function and vaginal health: baseline (T0) and 30 days after the third radiofrequency application (T3). In addition, for vaginal microbiota and cell maturation, four relevant time points will be considered based on a previous study [13]: baseline (T0) 30 days after the first application (T1), 30 days after second application (T2), and 30 days after the third radiofrequency application (T3). Primary outcomes consists of assessing female sexual function using the validated Portuguese version of the Female Sexual Function Index (FSFI). The FSFI is a brief scale for assessing sexual function in women. The latter is a written test with six subscales and one sum of scores that measure the degree of desire, excitement, lubrication, orgasm, satisfaction, and pain (dyspareunia).[19-21]

The secondary outcome will be vaginal health that will be evaluated per Vaginal Health Index (epithelial integrity, vaginal elasticity, moisture, fluid volume, pH vaginal), beyond the vaginal microbiota, and cell maturation. The Vaginal Health Score (VHI) consists of the clinical analysis during the specular examination of five parameters and is graded from 1 to 5. The sum of the values of the parameters evaluated results in the total vaginal health score. When the overall rating is less than 15, the vaginal mucosa is considered atrophic.[22]

Vaginal pH can be measured in different ways. Most studies describe the use of a pH indicator stripe on the lateral wall of the vagina.[23,24] Moreover, vaginal pH measurement is considered useful, practical, and inexpensive. For vaginal pH determination, the pH indicator strips will be applied against the vaginal wall. The pH will be measured by the gynecologist responsible for the procedure.

Vaginal smears will be obtained, which will be subsequently stained according to the standard Gram staining procedure for the classification of vaginal flora, following the criteria of Spiegel.[25] For analysis of vaginal cytology, vaginal smears will be obtained from the upper third of the right lateral vaginal wall, at predefined times. The material collected from the vaginal sac will be distributed on the blade, adequately identified and fixed, and subsequently stained by the Papanicolaou technique for determining the degree of maturation of the vaginal epithelium by the Frost Index.[26-28] The latter will be analyzed in the laboratory by two cytologists who are unaware of the women's identity and at what times of treatment the samples were obtained. The evaluation of the results is described in Table 1.

All possible adverse effects will be recorded and qualified during the period of treatment using questionnaires developed for this protocol. The adverse events will be reported in the results section of the manuscript and will be discussed. Any breaches of confidentiality, study protocol, or adverse events (AEs) attributable to this study will be reported to the research ethics committees.

Table 1. Outcome measurements

Outcome measurements	Explanation	Time point for assessment
FSFI	The FSFI evaluates six subscales and one sum of scores that measure the degree of desire, excitement, lubrication, orgasm, satisfaction, and pain (dyspareunia). The scores of the subscales are corrected and added up, resulting in a final score. Final scores can range from 2 to 36. Higher scores	T0 and T3

	indicate a better degree of sexual function[19,20]	
VHI	VHI scores of vaginal moisture, vaginal fluid volume, vaginal elasticity, pH, and vaginal epithelial integrity on a scale of 1 (most inferior) to 5 (best) will be found. Vaginal moisture is an assessment of the appearance or consistency of the secretions that line the vagina. Vaginal elasticity is a measurement of the vaginal tissue's ability to stretch at the examiner's touch. Epithelial integrity takes into account color, thickness, and the absence of vaginal bleeding. The lower the score, the higher the atrophy. [4] The sum of the values of the evaluated parameters results in the total vaginal health score. When the overall score is less than 15, the vaginal mucosa is considered atrophic.[22]	T0 and T3
Characterization of the vaginal ecosystem by Spiegel criteria	Vaginal flora will be classified, after gram stain according to the Spiegel Criteria, into type 1 (predominance of at least 85% lactobacilli), type 2 (balance between 50% lactobacilli and coccoid flora) and type 3 (0%, almost complete absence of lactobacilli with the presence of coccoidal flora).[25]	T0, T1, T2, and T3
Vaginal maturation	The slides will be examined by light microscopy, using a 10-magnification eyepiece and a 10X objective for the initial evaluation. Then, 100 cells will be analyzed with the same 40X objective	T0, T1, T2, and T3

and eyepiece in 5 randomly chosen fields. The percentage count of each cell type will be made, that is, parabasal, intermediate, and superficial cells (P / I / S), obtaining the cell maturation index or Frost index.[26] The maturation of the vaginal epithelium (positive effect of the treatment) is evidenced by a decrease in parabasal cells and an increase in the proportion of superficial cells.[27]

Follow-up

Data will be recorded during the follow-up period according to the multiple time points. The details are shown in Table 2.

Period 1: Screening time (day 0): before treatment.

Period 2: Intervention time (T1-T3): data will be recorded every seven days and 30 days during follow-up.

Period 3: The time after the intervention (within one year after treatment): follow-up at one year for long-term results.

Table 2. Schedule of enrollment, interventions, assessments and data collection

	Study Period				
	Enrollment / Baseline	Intervention			Follow-up
Time point	T0	T1	T2	T3	1 YEAR
Enrollment:	X				
Eligibility screen	X				
Informed consent	X				

Randomization	X				
Interventions:					
MAFRF		X	X	X	
Vaginal estrogens		X	X	X	
no treatment		X	X	X	
Assessments:					
General condition					X

Sample size

Therefore, with an equal 1:1:1 allocation rate, according to the results of a pilot study, where data came from 55 volunteers,[29] accepting an alpha of 0.05 and a beta risk <0.2 in a bilateral contrast, assuming a patient attrition rate at follow-up of approximately 15%–20%. The total sample size needed will be established at patients 198, 66 in each group (66 in the MAFRF group, 66 in with vaginal estrogens, and 66 in the as no treatment).

Randomization and allocation concealment

Eligible participants who provide written consent will be randomized into the Software Research Randomizer® programme. Randomization will be by block (1:1:1). Patients will be randomized into three intervention groups (MAFRF group, vaginal estrogens group, and no treatment group). In order to ensure allocation concealment, an offsite randomization schedule will be used. The randomization schedule will be prepared in advance by a researcher at the Federal University of Rio Grande do Norte (UFRN), who will have no contact with any participants throughout the trial and will not be involved in the recruitment, screening, assessment, enrollment or treatment process. To enroll a participant, the primary

1
2
3 researcher will email the consenting participant's name to the researcher at the
4
5 Federal University of Rio Grande do Norte (UFRN). These details will be entered
6
7 into the allocation spreadsheet, and the next treatment allocation and participant
8
9 identification number will be emailed directly to the treatment.
10
11
12
13

14 Blinding

15
16
17 Participants and the group researchers cannot be blind to arm allocation
18
19 because of the features of the interventions (MAFRF and vaginal estrogens).
20
21 However, the researchers that will evaluate the outcomes will be blinded to which
22
23 arm comprises each intervention and any other sociodemographic information that
24
25 might facilitate the identification of the intervention group.
26
27
28
29

30 Data management

31
32
33 Researchers qualified are crucial that ensure the quality of a clinical trial. The
34
35 researchers should understand the specific contents of the protocol. Data collection
36
37 will be performed by experienced staff using an online electronic data system. The
38
39 quality of the data management will be checked by the reliability, controlled access,
40
41 and traceability of the system. Data management will include baseline
42
43 characteristics (demographics, comorbidities, inclusion and exclusion criteria, and
44
45 blood test), potential confounder, and outcomes. Participants who withdraw from
46
47 our study for any reason will be followed up, and data will be analyzed according to
48
49 the intention-to-treat (ITT) principle. All randomized participants will be followed up
50
51 until one year after randomization.
52
53
54

55 Data extraction and statistical analysis

56
57
58
59
60

1
2
3 Data will be analyzed on an intention-to-treat basis, including all participants
4 enrolled in each group. Epidemiological and clinical characteristics data will be
5 analyzed using the chi-squared test, nonparametric Kruskal–Wallis test, and
6 analysis of variance. Analysis of percentages in each group (MAFRF, and no
7 treatment) compared with the control group (vaginal estrogens), for vaginal
8 maturation index, pH, vaginal health, and presence of lactobacilli will be performed
9 with the chi-squared and Fisher's exact tests. $P < 0.05$ will be considered statistically
10 significant. The software that will be used is SPSS for Windows, version 20.0 (IBM
11 Corp., Armonk, NY, USA).
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 Patient and public involvement

27
28 Neither patients nor public were involved in the development of the research
29 question, study design, outcome measures, recruitment to and conduct of the study
30 or assessment of the burden of the intervention. The results of the study will be
31 disseminated to study participants by means of lectures given by the investigators.
32
33
34
35
36
37
38
39

40 DISCUSSION

41
42 In this protocol, we described our randomized trial comparing the MAFRF to
43 estrogen vaginal and placebo in order to evaluate radiofrequency as a new
44 treatment option for GSM. The strengths of this trial are the randomized design that
45 allows control, by chance, of confounding factors, ease in forming the control group,
46 and ability for the analysis of several clinical outcomes simultaneously. The main
47 limitation is the loss of follow-up that occurs due to the extended treatment period.
48 It is recognized that vaginal estrogen may improve the symptoms of GSM.[21,28]
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Some systematic reviews have already been published on the subject.[30-
4
5 33] A recent study assessing the physical methods for the treatment of GSM showed
6
7 that, among physical methods, the CO2 laser continues one of the most commonly
8
9 used methods, as it has the largest body of scientific evidence. The CO2 laser has
10
11 been demonstrated to be an efficacious therapy for managing all GSM symptoms
12
13 up to 12 months after treatment. [33]. The VHI score improved concerning elasticity,
14
15 fluid volume, pH, epithelial integrity, vaginal moisture, and VAS scores improved
16
17 considerably for sensitivity, vaginal dryness, itching/stinging, dyspareunia, and
18
19 dysuria. The studies about the Er: YAG treatment showed that this method is
20
21 effective, practical, and safe too, and the effects are rapid and sustained for at least
22
23 12 months. Application of Er: YAG laser is associated with an improvement in
24
25 vaginal atrophy, and such treatment induced a significant decrease in VAS, an
26
27 increase of VHIS, and a substantial improvement in the urinary incontinence
28
29 (UI).[33]
30
31
32
33
34

35 Additionally, the RF method could be a safe and effective non-surgical option
36
37 for treating mild to moderate UI and other symptoms related to GSM. Significant
38
39 improvements were observed in the mean VAS score and for complaints of VVA.
40
41 However, little is known about the actual effectiveness of RF in the treatment of
42
43 GSM/UI since, as we have already reported in this review, the current literature is
44
45 still sparse for this topic. For this reason, new research about this topic is
46
47 necessary.[33]
48
49
50

51 We can also quote a prospective study[29] conducted at a public university
52
53 hospital to evaluate the effectiveness of MAFRF in the non-hormonal treatment of
54
55 GSM. In this research, 55 postmenopausal women were examined before and after
56
57 the treatment about the VHI, vaginal microbiota, vaginal pH, and cell maturation.
58
59
60

1
2
3 The latter study observed after treatment an increase in the percentage of
4 *Lactobacillus spp.* Consequently, occurred a progressive decrease in vaginal pH.
5
6 Regarding cell maturation, there was a decrease in the percentage of parabasal
7 cells and an increase in the rate of superficial cells. Additionally, there was an
8 improvement in the VHI index. In conclusion, the results showed that the therapy
9 of MAFRF restored the vaginal balance, as would usually be expected with sufficient
10 estrogen levels. The predominance of *Lactobacillus* species and acidic pH of the
11 vaginal fluid achieved after radiofrequency therapy could protect postmenopausal
12 women from vaginal infections, inflammation, and infections of the urogenital tract.
13 Therefore, the MAFRF treatment was considered well-tolerated and promoted
14 significant improvement in the vaginal microenvironment; therefore, radiofrequency
15 could be an option for GSM symptoms.[29]

16
17 Although the laser is the most well-known and used physical method, using
18 radiofrequency presents advantages, such as the application is realized under direct
19 vision, and there is the use of a vaginal speculum, facilitating treatment along the
20 vaginal walls and preventing overlapping of shots. As well as this, the method is
21 easy to learn and less costly. The procedure features a useful tolerance index, the
22 patients recovered quickly, and the microablation disappeared 3 to 5 days after the
23 application.

24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 **ETHICS AND DISSEMINATION**

50
51 All the procedures performed in this study involving human participants will be
52 conducted following the ethical standards of the 1964 Declaration of Helsinki and its
53 later amendments, the Declaration of Madrid of the World Psychiatric Association,
54 and the established requirements for manuscripts submitted to biomedical journals
55
56
57
58
59
60

1
2
3 or comparable ethical standards of good clinical practice. The trial was approved by
4
5 the local Division Ethics Committee of University Hospital Onofre Lopes (UFRN),
6
7 under the number CAAE 81973618.2.0000.5292 (date of approval: April 17, 2018;
8
9 reference number: CAAE 81973618.2.0000.5292) and was registered in REBEC
10
11 (Brazilian Registry of Clinical Trials) under number RBR-94DX93. Before
12
13 enrollment of trial participants. Data confidentiality will be assured through data
14
15 anonymization.
16
17
18
19
20

21 REFERENCES

- 22
23
24
25 1. Management of symptomatic vulvovaginal atrophy: 2013 position statement
26
27 of The North American Menopause Society. *Menopause* 2013;20(9):888–
28
29 902.
30
31
- 32 2. Portman DJ, Gass MLS. Vulvovaginal Atrophy Terminology Consensus
33
34 Conference Panel. Genitourinary syndrome of menopause: new terminology
35
36 for vulvovaginal atrophy from the International Society for the Study of
37
38 Women's Sexual Health and the North American Menopause Society.
39
40 *Maturitas* 2014;79(3):349–54.
41
42
- 43 3. Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause:
44
45 an overview of clinical manifestations, pathophysiology, etiology, evaluation,
46
47 and management. *Am J Obstet Gynecol* 2016;215:704-711.
48
49
- 50 4. Tzur T, Yohai D, Weintraub AY. The role of local estrogen therapy in the
51
52 management of pelvic floor disorders. *Climacteric* 2016;19:162-171.
53
54
- 55 5. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in
56
57 postmenopausal women. *Cochrane Database Syst Rev* 2016;8:CD001500.
58
59
60

- 1
2
3 6. Filippini M, Luvero D, Salvatore S, Pieralli A, Montera R, Plotti F, et al.
4
5 Efficacy of fractional CO2 laser treatment in postmenopausal women with
6
7 genitourinary syndrome. *Menopause*. 2019;1(27):000-000.
8
9
- 10 7. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al.
11
12 A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a
13
14 pilot study. *Climacteric*. 2014;17(4):363–369.
15
16
- 17 8. Athanasiou S, Pitsouni E, Falagas ME, Salvatore S, Grigoriadis T. CO 2 -
18
19 laser for the genitourinary syndrome of menopause. How many laser
20
21 sessions? *Maturitas*. 2017;104:24–28.
22
23
- 24 9. Gambacciani M, Levancini M. Vaginal erbium laser as second-generation
25
26 thermotherapy for the genitourinary syndrome of menopause. *Menopause*.
27
28 2017; 24(3):316–319.
29
30
- 31 10. Flint R, Cardozo L, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S.
32
33 Rationale and design for fractional microablative CO2 laser versus
34
35 photothermal non-ablative erbium:YAG laser for the management of
36
37 genitourinary syndrome of menopause: a non-inferiority, single-blind
38
39 randomized controlled trial. *Climacteric*. 2019;1–5.
40
41
- 42 11. Vicariotto F, DE Seta F, Faoro V, et al. Dynamic
43
44 quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-
45
46 vaginal atrophy: 12-month efficacy and safety. *Minerva Ginecol* 2017;69:
47
48 342-349.
49
50
- 51 12. Casabona G, Presti C, Manzini M, et al. Fractional ablative radiofrequency:
52
53 a pilot study with twenty cases involving rejuvenation of the lower eyelid.
54
55 *Surg Cosmet Dermatol* 2014;6(1):50-5.
56
57
58
59
60

- 1
2
3 13. Kamilos MF, Borelli CL. New therapeutic option in genitourinary syndrome
4 of menopause: pilot study using microablative fractional radiofrequency.
5
6 *Einstein* 2017;(15):445-51.
7
8
9
- 10 14. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
11 SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
12 trials. *BMJ* 2013;346:e7586.
13
14
15
16
- 17 15. Schulz KF, Altman DG, Moher D. CONSORT 2010: updated guidelines for
18 reporting parallel group randomised trials. *Ann Intern Med* 2010;152:1–8.
19
20
- 21 16. Constantine GD, Simon JA, Pickar JH, et al; REJOICE Study Group. The
22 REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety
23 and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic
24 vulvar and vaginal atrophy. *Menopause* 2017;24(4):409-416.
25
26
27
28
29
- 30 17. Simon JA, Archer DF, Constantine GD, et al. A vaginal estradiol softgel
31 capsule, TX-004HR, has negligible to very low systemic absorption of
32 estradiol: efficacy and pharmacokinetic data review. *Maturitas* 2017;99:51-
33 58.
34
35
36
37
38
39
- 40 18. Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause:
41 Management Strategies for the Clinician. *Mayo Clin Proc* 2017;92(12):1842-
42 1849.
43
44
45
46
- 47 19. Thiel R, Dambros M, Palma PCR, Thiel M, Riccetto CLZ, Ramos MF.
48 [Translation into Portuguese, cross-national adaption and validation of the
49 Female Sexual Function Index]. *Rev Bras Ginecol Obstet.* 2008;30(10):504-
50 510. Portuguese
51
52
53
54
55
56
57
58
59
60

- 1
2
3 20. Hentschel H, Alberton DL, Capp E, Goldim JR, Passos EP. Validation of the
4 Female Sexual Function Index (FSFI) for portuguese language. *Rev. HCPA*
5 2007;27(1).
6
7
8
9
10 21. Davis SR. Understanding female sexual function. *Menopause*. 16. 2009;(3):425–
11 6, doi:10.1097/gme.0b013e31819c67a7.
12
13
14 22. Lustosa AB, Girão MJBC, Sartori MGF, et al. Urinary and Vaginal Cytology
15 of Postmenopausal Women with Oral and Transdermal Estrogen
16 Replacement. *RBGO* 2002; 24, (9):573-577.
17
18
19
20 23. Lee YK, Chung HH, Kim JW, et al. Vaginal pH balanced gel for the control
21 of atrophic vaginitis among breast cancer survivors: a randomized controlled
22 trial. *Obstet Gynecol* 2011;117(4):922-927.
23
24
25
26 24. Ekin M, Yasar L, Savan K, et al. The comparison of hyaluronic acid vaginal
27 tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a
28 randomized controlled trial. *Arch Gynecol Obstet* 2011;283(3):539-543.
29
30
31
32 25. Spiegel CA, Amsel LR. Diagnosis of bacterial vaginosis by direct gram stain
33 of vaginal fluid. *J. Clin Microbiol* 1983;18:170-72.
34
35
36
37 26. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic
38 vaginitis. *Am Fam Physician*. 2000;61(10):3090-6.
39
40
41
42 27. Lencioni LJ. Citologia endócrina. 1ª ed. Buenos Aires: *Médica Pan*
43 *Americana* 1987.
44
45
46
47 28. Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in
48 postmenopausal women: findings from the REVIVE (Real Women's Views
49 of Treatment Options for Menopausal Vaginal Changes) survey. *The J. Sex.*
50 *Med* 2013;10(7):1790-1799. doi: 10.1111/jsm.12190.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 29. Sarmiento AC, Fernandes FS, Marconi C, et al. Impact of microablative
4 fractional radiofrequency on the vaginal health, microbiota, and cellularity o
5 postmenopausal women. *CLINICS*. 2020;75:1750.
6
7
8
9
10 30. Athanasiou S, Pitsouni E, Douskos A, Salvatore S, Loutradis D, Grigoriadis
11 T. Intravaginal energy-based devices and sexual health of female cancer
12 survivors: a systematic review and meta-analysis. *Lasers in Medical*
13 *Science*. 2019.
14
15
16
17
18 31. Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas ME, Athanasiou
19 S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual
20 function and orgasm of menopausal women: A systematic review and meta-
21 analysis of randomized controlled trials. *European Journal of Obstetrics &*
22 *Gynecology and Reproductive Biology*. 2018;229:45–56.
23
24
25
26
27
28
29
30 32. Jha S, Wyld L, Krishnaswamy PH. The impact of vaginal laser treatment for
31 genitourinary syndrome of the menopause in breast cancer survivors: a
32 systematic review and meta-analysis. *Clinical Breast Cancer*.
33 2019;19(4):556-562.
34
35
36
37
38
39
40 33. Sarmiento ACA, Lírio JF, Medeiros KS, et al. Physical methods for the
41 treatment of genitourinary syndrome of menopause: A systematic review.
42 *IJGO*. 2020;153(2):200-219.
43
44
45
46
47
48

49 **Authors' contributions:** ACAS, AKG were involved in drafting the study protocol.
50
51 KM and APFC were involved in statistical planning and drafting of the study protocol.
52
53 JCC and FSF were involved in drafting and revising the study protocol. AKG
54 developed the idea for this trial and was involved in drafting and revising the study
55 protocol. ACAS conceived and designed the concept for this trial, was involved in
56
57
58
59
60

1
2
3 drafting and revising the study protocol and was the trial's principal investigator. All
4 authors are involved in data acquisition and approved the final version of the
5 manuscript.
6
7
8
9

10 **Conflict of interest statement:** The authors report no conflict of interest.
11
12

13 **Funding:** This work was supported by Brazilian CNPq (National Council for
14 Scientific and Technological Development). Grant number 436740/2018-4.
15
16

17 **Disclaimer:** These funding sources have no role in the design of this study and will
18 not have any role during its execution, analyses, interpretation of the data, or
19 decision to submit results.
20
21
22

23 **Data sharing statement:** All investigators will maintain full autonomy and
24 involvement in the design, conduct and reporting of the trial with everyone having
25 full access to the final data.
26
27
28

29 **Confidentiality:** The original documents and files will be kept at the trial sites for
30 15 years. The lead investigator is responsible for data and file storage. The lead
31 investigator is responsible for data and files storage for 15 years.
32
33
34

35 **Consent or assent:** All participants will be asked to sign an informed consent form
36 to join the trial. The form explicitly contains all stages of research.
37
38

39 **Ethics approval:** The trial was approved by the local Division Ethics Committee
40 (date of approval: April 17, 2018; reference number: 81973618.2.0000.5292) and
41 registered in the Brazilian Clinical Trials Registry - REBEC: RBR-94DX93.
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Figure legend:**
56

57 **Figure 1. CONSORT 2010 Flow Diagram**
58
59
60




Figure 1. CONSORT 2010 Flow Diagram

Figure 1. CONSORT 2010 Flow Diagram

189x222mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	01
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	01
	2b	All items from the World Health Organization Trial Registration Data Set	01
Protocol version	3	Date and version identifier	01
Funding	4	Sources and types of financial, material, and other support	01
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	01
	5b	Name and contact information for the trial sponsor	X
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	X
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	X

1	Introduction			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	04-05
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	05
7				
8	Objectives	7	Specific objectives or hypotheses	06
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	06
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	06
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	07
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	07-08
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	07
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	07-08
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	09
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	09-10
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
35			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	12-13
39			participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	13
5				
6				
7	Methods: Assignment of interventions (for controlled trials)			
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	13
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	13
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	13
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	14
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	14
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	15-16
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15-16
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	14
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	14-15
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	15
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	X
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	X
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	10
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	X
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	23
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	23
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	X
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	23
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	23
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	23
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	X
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	X
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	X
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	X
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	✓
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	X
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.

BMJ Open

Microablative Fractional Radiofrequency for the genitourinary syndrome of menopause: protocol of randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046372.R2
Article Type:	Protocol
Date Submitted by the Author:	02-Jun-2021
Complete List of Authors:	Sarmiento, Ayane Cristine ; Universidade Federal do Rio Grande do Norte Fernandes, Fabíola; Universidade Federal do Rio Grande do Norte Costa, Ana Paula; Universidade Federal do Rio Grande do Norte Medeiros, Kleyton ; Universidade Federal do Rio Grande do Norte Crispim, Janaina; Universidade Federal do Rio Grande do Norte Gonçalves, Ana; Universidade Federal do Rio Grande do Norte
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Sexual health, Medical management
Keywords:	GYNAECOLOGY, Sexual dysfunction < UROLOGY, SEXUAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Microablative Fractional Radiofrequency for the genitourinary syndrome**
4 **of menopause: protocol of randomized controlled trial**
5
6
7
8

9 Ayane Cristine Alves Sarmiento¹, Fabíola Sephora Fernandes², Ana Paula Ferreira
10 Costa¹, Kleyton Medeiros¹, Janaina C. Crispim², Ana Katherine Gonçalves^{1,3*}
11
12

13 ¹ Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte
14 (UFRN), Natal, RN, Brazil. E-mail: ayane_cris@hotmail.com / [ana-paula-
16 rf@hotmail.com](mailto:ana-paula-
15 rf@hotmail.com) / kleyton_medeiros@hotmail.com
17
18

19 ² Department of Clinical Analysis and Toxicology, Federal University of Rio Grande
20 do Norte, Natal, Brazil. E-mail: fabiolasbp@gmail.com / janacrispimfre@gmail.com
21
22

23 ³ Department of obstetrics and gynaecology, Federal University of Rio Grande do
24 Norte (UFRN), Natal, RN, Brazil. E-mail: anakatherine_ufrnet@yahoo.com.br
25
26
27
28

29 *Correspondence
30

31 Ana Katherine Gonçalves
32

33 Email: anakatherine_ufrnet@yahoo.com.br (AKG)
34

35 ORCID ID: <https://orcid.org/0000-0002-8351-5119>
36
37
38

39 **Word count: 2.791**
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve. These changes have consequences: vaginal dryness, dyspareunia, discomfort, burning and irritation, vulvovaginal pruritus, dysuria, and increased frequency of genitourinary infections. The therapy more suitable for vaginal symptoms in post-menopause yet is the use of a topical hormone. However, the prescription of topical estrogens should also be avoided in women with a history of breast cancer, estrogen-sensitive tumors, and thromboembolism, emphasizing the necessity of alternative treatments. Recently, physical methods, such as laser and radiofrequency (RF), in their non-ablative, ablative, and micro-ablative forms, have been used in the vaginal mucosa to promote neocolagenesis and neoelastogenesis. This randomized study aims to compare the efficiency of Microablative Fractional Radiofrequency (MAFRF) treatment with vaginal estrogens and no treatment.

Methods and analyses: This randomized, controlled clinical intervention trial with an open-label design comparing the treatment of MAFRF with vaginal estrogens and no treatment. Four important moments were considered to evaluate treatment results (T0, T1, T2, and T3). The primary outcome includes vulvovaginal atrophy (vaginal pain, burning, itching, dryness, dyspareunia, and dysuria), and the secondary outcomes will be sexual function, vaginal health (epithelial integrity, vaginal elasticity, moisture, fluid volume, and pH vaginal), and quality of life.

Ethics and dissemination: Due to the nature of the study, we obtained approval from the Ethics Committee. All participants must sign an informed consent form before randomization. The results of this study will be published in peer-reviewed journals. The data collected will also be available in a public repository of data.

Trial registration number: Registered in REBEC (Brazilian Registry of Clinical Trials) under number RBR-94DX93. This study was approved by the Division Ethics Committee of University Hospital Onofre Lopes (UFRN), under CAAE 81973618.2.0000.5292.

Keywords: Menopause; Radiofrequency; Laser; Lactobacillus; Therapeutics.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The latter is the first randomized controlled trial comparing the MAFRF with the golden standard (vaginal estrogen).
- Inclusion criteria allow homogeneity of subjects and less risk of bias.
- Blinding of assessors and standardization of protocols enhance this trial's internal validity.
- The study will be performed among postmenopausal women; thus, its results may not be generalizable to other populations.

INTRODUCTION

Menopause is a physiological and progressive phenomenon, secondary to decreased ovarian follicular reserve. Estrogen deficiency is responsible for the mucosa vulvovaginal thinning of the squamous epithelium, a decrease in the number of collagen and elastin fibers, impaired cell function, reduction in the number of vessel changes in vaginal pH, and in flora commensal.[1]

These changes have functional consequences, being vaginal dryness, dyspareunia, sensations of discomfort, burning and irritation, vulvovaginal pruritus, dysuria, and increased frequency of genitourinary infections.[1] The term Genitourinary Syndrome of Menopause (GSM) was defined in 2014 at a North American consensus conference, where all the disabling symptoms of the urogenital sphere secondary to menopause were more fully and objectively identified.[2]

The therapy more suitable for vaginal symptoms in post menopause yet is the use of the topical hormone, once promote the renovation of the epithelium and vaginal flora, also improves the vulvovaginal atrophy symptoms (VVA).[3] Besides that, the use of low-dose vaginal estrogen has demonstrated to be superior to systemic therapy for improvement VVA.[4] However, a major limitation is associated with low adherence to treatment, due to multiple and inconvenient self-applications and increased vaginal discharge. We cannot fail to emphasize that the prescription of topical estrogens should be avoided in women with a history of breast cancer, estrogen-sensitive tumors, and thromboembolism. For these reasons are necessary to search for alternatives to treatment.[5]

The use of fractional micro ablative CO2 laser therapy was approved in 2014, the Food and Drug Administration (FDA), but only for genitourinary surgery. Considering the context of the treatment of GSM, in order to avoid hormonal

1
2
3 interventions, the micro-ablative fractional CO2 laser, or the non-ablative vaginal
4 erbium YAG laser can be considered. Recently, studies showed that the use of
5 fractional CO2 laser in the treatment of VVA was beneficial, effective, and safe. The
6 latter positive effects on VVA symptoms can be improved not only the quality of life;
7 but also the aspect of sexual pain; and other dimensions of women's sexual
8 response, such as desire, initiative, and receptivity to their sexual partner.[6-8]
9
10 Similar results have been observed in the use of YAG laser treatment. Application
11 of Er: YAG laser is associated with an improvement in vaginal atrophy, and such
12 treatment induced a significant decrease in Visual Analog Scale (VAS), an increase
13 of VHI, and a significant improvement in urinary incontinence.[9,10] Beyond the
14 laser, other non-ablative electromagnetic energy, such as radiofrequency, are being
15 considered for this indication.[11]

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 Radiofrequency (RF) is a technique that involves cutting and coagulating
32 biological tissues by using a high-frequency alternating current, which instantly
33 raises the intracellular temperature to 100°C, thus determining cellular membrane
34 expansion and rupture. By reaching the frequency of 4,000,000 cycles/second
35 (4MHz), the FM radio frequency is obtained – this feature giving rise to the name
36 RF electrosurgery. Microablative fractional radiofrequency (MAFRF) is a new
37 procedure that uses random energy in a fractionation system that observes the
38 thermal relaxation of the tissue at a certain time. Energy fractionation consists of
39 energy distribution at equidistant points, producing microscopic columns of thermal
40 injuries in the epidermis and upper dermis, resulting in microscopic columns of
41 treated tissue and intervening areas of untreated skin, which in turn achieve faster
42 reepithelialization.[12,13]
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We can consider that the current literature lacks still needs research
4 regarding the use of radiofrequency for the treatment of GSM, most publications
5 evaluate only use the laser. The few studies that have been done on radiofrequency,
6
7 are mostly restricted to results on sexual function and quality of life. There are no
8 results about the clinical evaluations as pH, cellularity, and vaginal flora when using
9 radio frequency, and that is exactly our proposal.
10
11
12
13
14
15
16
17
18

19 Objectives

20
21 We aim to investigate the therapeutic effect of vaginal MARFM in the GSM.
22 We postulate that MAFRF could promote the improvement of vulvovaginal atrophy.
23 Furthermore, it could improve sexual function, vaginal health, and quality of life in
24 postmenopausal women.
25
26
27
28
29
30
31
32

33 **METHODS AND ANALYSIS**

34
35 This protocol will adhere to the Standard Protocol Items for Randomized
36 Trials (SPIRIT)[14] and CONSORT statements.[15]
37
38
39
40
41

42 Trial design

43
44 The study is a randomized protocol, controlled clinical intervention trial with
45 a single-blind design comparing treatment with MAFRF with vaginal estrogens as
46 well as no treatment.
47
48
49
50
51
52

53 Population

54
55 Participant recruitment is currently ongoing at a gynecological Unit of a public
56 university hospital. Patients who fulfill the inclusion criteria and who sign the free
57
58
59
60

1
2
3 and informed consent forms will enter the screening period. Patients who meet the
4
5 exclusion criteria will be excluded before randomization.
6
7
8
9

10 Eligibility criteria and recruitment

11
12 The treatments will be conducted at one biggest gynecological unit of
13
14 a public university Hospital Brazil. Participants will be sought via referrals from
15
16 gynecologists physicians that attend in this hospital. The study will include healthy
17
18 postmenopausal women (55 to 65 years old, with whom at least 12 months have
19
20 passed since last menstrual period or bilateral oophorectomy), who are still sexually
21
22 active, with GSM, plasma gonadotropin and presenting serum estradiol levels in the
23
24 postmenopausal range (FSH >40 U/L; estradiol <25 pg/ml) as well as negative
25
26 Papanicolaou (Pap) smear for cervical cancer precursor cells. Women who have
27
28 used any form of hormonal (systemic or local) therapy in the last six months,
29
30 lubricants or vaginal moisturizers in the past month, suffering from active genital
31
32 infections (diagnosis by GRAM stain and Multiplex-PCR), and any disease that
33
34 would interfere following the protocol will be excluded. Figure1 shows the study flow.
35
36
37
38
39
40
41
42

43 Interventions

44 The microablative fractional radiofrequency (MAFRF) will be performed
45
46 according to the technique described by Kamilos and Borelli.[13] for the procedure,
47
48 the Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX
49
50 system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic
51
52 circuit of energy fractionation, connected to a vaginal pen with 64 microneedles,
53
54 200 μ in diameter and 1mm in length, mounted on a Teflon body and divided into an
55
56 eight-column matrix with eight needles each.[13]
57
58
59
60

1
2
3 In the vestibule and vaginal opening, 10% lidocaine spray will be applied 3
4 minutes before the procedure. Three applications will be realized in the
5 vagina/vaginal introitus, with intervals of 30 days. A sequential application will be
6 performed on the vaginal walls under direct vision. For the post-treatment care, the
7 use of 5% dexpanthenol solution in the vaginal opening will be recommended two
8 to three times a day, for 2 to 5 days. With no intercourse for ten days.[13] The
9 procedure will be performed in the outpatient clinic by an experienced gynecologist,
10 and a single gynecologist supervises the carrying out of the whole process for the
11 entire period of the research.
12
13
14
15
16
17
18
19
20
21
22

23
24 The patients from the group with estrogen will be instructed to use
25 Promestriene (Estradiol 3-propyl 17 β -methyl diether) vaginal cream, 1g
26 corresponding to the use of the filled applicator up to the ring mark, twice a week,
27 for three months.[16-18]
28
29
30
31
32

33 The patients who did not receive any intervention will be instructed to attend
34 the consultation for follow-up according to what was established in the study
35 protocol.
36
37
38
39
40
41

42 Questionnaire

43
44 In the first query, the women will answer a standardized questionnaire with
45 information on demographic characteristics including age, time menopause, skin
46 color, schooling, and socioeconomic classification.
47
48
49
50
51

52 Outcomes

53
54 Four relevant time points will be considered for evaluating the results based
55 on a previous study [13]: baseline (T0) 30 days after the first application (T1), 30
56
57
58
59
60

1
2
3 days after the second application (T2), and 30 days after the third radiofrequency
4 application (T3).
5

6
7 The primary outcome includes vulvovaginal atrophy using the 11-point Visual
8 Analog Scale (VAS). The VAS associate symptoms (vaginal pain, burning, itching,
9 dryness, dyspareunia, and dysuria).[19-22]
10
11

12
13 Secondary outcomes will be sexual function, vaginal health (epithelial integrity,
14 vaginal elasticity, moisture, fluid volume, and pH vaginal), and quality of life. Female
15 sexual function will be evaluated using the validated Portuguese version of the
16 Female Sexual Function Index (FSFI). FSFI is a brief scale for assessing sexual
17 function in women. The latter is a written test with six subscales and one sum of
18 scores that measure the degree of desire, excitement, lubrication, orgasm,
19 satisfaction, and pain (dyspareunia).[23-25].
20
21

22
23 The Short Form 12 (SF-12) is a self-reported outcome measure assessing the
24 impact of health on an individual's everyday life. The Sf-12 assesses the physical
25 (PCS12), and mental (MCS12) component summary scores of It is often used as a
26 quality of life measure.[20-22,26] Vaginal health will be evaluated per Vaginal Health
27 Score (VHI). The VHI consists of the clinical analysis during the specular
28 examination of five parameters and is graded from 1 to 5. The sum of the values of
29 the parameters evaluated results in the total vaginal health score.[19,27] The
30 evaluation of the results is described in Table 1.
31
32

33
34 All possible adverse effects will be recorded and qualified during the period
35 of treatment using questionnaires developed for this protocol. The adverse events
36 will be reported in the results section of the manuscript and will be discussed. Any
37 breaches of confidentiality, study protocol, or adverse events (AEs) attributable to
38 this study will be reported to the research ethics committees.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Outcome measurements

Outcome measurements	Explanation	Time point for assessment
VAS	VAS evaluates the change in 6 categories of symptoms commonly associated with VVA: vaginal pain, burning, itching, dryness, dyspareunia, and dysuria. VAS will be scored on an 11-point scale for each symptom with 0 being the lowest level (none) and 10 being the highest (extreme).[19-22]	T0, T1, T2, and T3
FSFI	The FSFI evaluates six subscales and one sum of scores that measure the degree of desire, excitement, lubrication, orgasm, satisfaction, and pain (dyspareunia). The scores of the subscales are corrected and added up, resulting in a final score. Final scores can range from 2 to 36. Higher scores indicate a better degree of sexual function.[23-25]	T0, T1, T2, and T3
VHI	VHI scores of vaginal moisture, vaginal fluid volume, vaginal elasticity, pH, and vaginal epithelial integrity on a scale of 1 (most inferior) to 5 (best) will be found. Vaginal moisture is an assessment of the appearance or consistency of the secretions that line the vagina. Vaginal elasticity is a measurement of the vaginal tissue's ability to stretch at the examiner's touch. Epithelial integrity	T0, T1, T2, and T3

	takes into account color, thickness, and the absence of vaginal bleeding. The lower the score, the higher the atrophy. [4] The sum of the values of the evaluated parameters results in the total vaginal health score. When the overall score is less than 15, the vaginal mucosa is considered atrophic.[19,27]	
SF-12	The SF-12 provides accurate and efficient information to assess physical and mental health. It includes 8 dimensions as the initial SF-36 instrument: general health perceptions (1 item), physical functioning (2 items), role limitations due to physical problems (2 items), bodily pain (1 item), vitality (1 item), social functioning (1 item), role limitations due to emotional problems (2 items), and mental health (2 items). The composite physical (PCS) and mental health (MCS) scores are computed using the scores of the 12 items, ranging from 0 to 100, where zero reflects the lowest health level and 100 the highest level.[20-22,26]	T0, T1, T2, and T3

Follow-up

Data will be recorded during the follow-up period according to the multiple time points. The details are shown in Table 2.

Period 1: Screening time (day 0): before treatment.

Period 2: Intervention time (T1-T3): data will be recorded every seven days and 30 days during follow-up.

Period 3: The time after the intervention (within one year after treatment): follow-up at one year for long-term results.

Table 2. Schedule of enrollment, interventions, assessments and data collection

	Study Period				
	Enrollment / Baseline	Intervention			Follow-up
Time point	T0	T1	T2	T3	1 YEAR
Enrollment:	X				
Eligibility screen	X				
Informed consent	X				
Randomization	X				
Interventions:					
MAFRF		X	X	X	
Vaginal estrogens		X	X	X	
no treatment		X	X	X	
Assessments:					
General condition					X

Sample size

Therefore, with an equal 1:1:1 allocation rate, according to the results of a pilot study, where data came from 55 volunteers,[28] accepting an alpha of 0.05 and a beta risk <0.2 in a bilateral contrast, assuming a patient attrition rate at follow-up of approximately 15%–20%. The total sample size needed will be established at patients 198, 66 in each group (66 in the MAFRF group, 66 in with vaginal estrogens, and 66 in the as no treatment).

Randomization and allocation concealment

Eligible participants who provide written consent will be randomized into the Software Research Randomizer® programme. Randomization will be by block (1:1:1). Patients will be randomized into three intervention groups (MAFRF group, vaginal estrogens group, and no treatment group). In order to ensure allocation concealment, an offsite randomization schedule will be used. The randomization schedule will be prepared in advance by a researcher at the Federal University of Rio Grande do Norte (UFRN), who will have no contact with any participants throughout the trial and will not be involved in the recruitment, screening, assessment, enrollment or treatment process. To enroll a participant, the primary researcher will email the consenting participant's name to the researcher at the Federal University of Rio Grande do Norte (UFRN). These details will be entered into the allocation spreadsheet, and the next treatment allocation and participant identification number will be emailed directly to the treatment.

Blinding

Participants and the group researchers cannot be blind to arm allocation because of the features of the interventions (MAFRF and vaginal estrogens). However, the researchers that will evaluate the outcomes will be blinded to which arm comprises each intervention and any other sociodemographic information that might facilitate the identification of the intervention group.

Data management

Researchers qualified are crucial that ensure the quality of a clinical trial. The researchers should understand the specific contents of the protocol. Data collection

1
2
3 will be performed by experienced staff using an online electronic data system. The
4
5 quality of the data management will be checked by the reliability, controlled access,
6
7 and traceability of the system. Data management will include baseline
8
9 characteristics (demographics, comorbidities, inclusion and exclusion criteria, and
10
11 blood test), potential confounder, and outcomes. Participants who withdraw from
12
13 our study for any reason will be followed up, and data will be analyzed according to
14
15 the intention-to-treat (ITT) principle. All randomized participants will be followed up
16
17 until one year after randomization.
18
19
20
21
22

23 24 Data extraction and statistical analysis

25
26 Data will be analyzed on an intention-to-treat basis, including all participants
27
28 enrolled in each group. Epidemiological and clinical characteristics data will be
29
30 analyzed using the chi-squared test, nonparametric Kruskal–Wallis test, and
31
32 analysis of variance. Data presented in the text and tables will be reported as mean
33
34 and standard deviation, median, and percentage (%). Continuous variables will be
35
36 analyzed by using the paired t-test and the signed-rank test accordingly to data
37
38 distribution. $P < 0.05$ will be considered statistically significant. The software that
39
40 will be used is SPSS for Windows, version 20.0 (IBM Corp., Armonk, NY, USA).
41
42
43
44
45
46

47 Patient and public involvement

48
49 Neither patients nor public were involved in the development of the research
50
51 question, study design, outcome measures, recruitment to and conduct of the study
52
53 or assessment of the burden of the intervention. The results of the study will be
54
55 disseminated to study participants by means of lectures given by the investigators.
56
57
58
59
60

DISCUSSION

In this protocol, we described our randomized trial comparing the MAFRF to estrogen vaginal and placebo in order to evaluate radiofrequency as a new treatment option for GSM. The strengths of this trial are the randomized design that allows control, by chance, of confounding factors, ease in forming the control group, and ability for the analysis of several clinical outcomes simultaneously. The main limitation is the loss of follow-up that occurs due to the extended treatment period. It is recognized that vaginal estrogen may improve the symptoms of GSM.[21,28]

Some systematic reviews have already been published on the subject.[29-32] A recent study assessing the physical methods for the treatment of SGM showed that, among physical methods, the CO2 laser continues one of the most commonly used methods, as it has the largest body of scientific evidence. The CO2 laser has been demonstrated to be an efficacious therapy for managing all GSM symptoms up to 12 months after treatment.[32] The VHI score improved concerning elasticity, fluid volume, pH, epithelial integrity, vaginal moisture, and VAS scores improved considerably for sensitivity, vaginal dryness, itching/stinging, dyspareunia, and dysuria. The studies about the Er: YAG treatment showed that this method is effective, practical, and safe too, and the effects are rapid and sustained for at least 12 months. Application of Er: YAG laser is associated with an improvement in vaginal atrophy, and such treatment induced a significant decrease in VAS, an increase of VHIS, and a substantial improvement in the urinary incontinence (UI).[32]

Additionally, the RF method could be a safe and effective non-surgical option for treating mild to moderate UI and other symptoms related to GSM. Significant improvements were observed in the mean VAS score and for complaints of VVA.

1
2
3 However, little is known about the actual effectiveness of RF in the treatment of
4 GSM/UI since, as we have already reported in this review, the current literature is
5 still sparse for this topic. For this reason, new research about this topic is
6 necessary.[32]
7
8
9
10

11
12 We can also quote a prospective study[28] conducted at a public university
13 hospital to evaluate the effectiveness of MAFRF in the non-hormonal treatment of
14 GSM. In this research, 55 postmenopausal women were examined before and after
15 the treatment about the VHI, vaginal microbiota, vaginal pH, and cell maturation.
16 The latter study observed after treatment an increase in the percentage of
17 *Lactobacillus spp.* Consequently, occurred a progressive decrease in vaginal pH.
18 Regarding cell maturation, there was a decrease in the percentage of parabasal
19 cells and an increase in the rate of superficial cells. Additionally, there was an
20 improvement in the VHI index. In conclusion, the results showed that the therapy
21 of MAFRF restored the vaginal balance, as would usually be expected with sufficient
22 estrogen levels. The predominance of *Lactobacillus* species and acidic pH of the
23 vaginal fluid achieved after radiofrequency therapy could protect postmenopausal
24 women from vaginal infections, inflammation, and infections of the urogenital tract.
25 Therefore, the MAFRF treatment was considered well-tolerated and promoted
26 significant improvement in the vaginal microenvironment; therefore, radiofrequency
27 could be an option for GSM symptoms.[28]
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Although the laser is the most well-known and used physical method, using
50 radiofrequency presents advantages, such as the application is realized under direct
51 vision, and there is the use of a vaginal speculum, facilitating treatment along the
52 vaginal walls and preventing overlapping of shots. As well as this, the method is
53 easy to learn and less costly. The procedure features a useful tolerance index, the
54
55
56
57
58
59
60

1
2
3 patients recovered quickly, and the microablation disappeared 3 to 5 days after the
4
5 application.
6
7
8
9

10 **ETHICS AND DISSEMINATION**

11
12 All the procedures performed in this study involving human participants will be
13
14 conducted in accordance with the ethical standards of the 1964 Declaration of
15
16 Helsinki and its later amendments, the Declaration of Madrid of the World
17
18 Psychiatric Association and the established requirements for manuscripts submitted
19
20 to biomedical journals or comparable ethical standards of good clinical practice. The
21
22 trial was approved by the local Division Ethics Committee of University Hospital
23
24 Onofre Lopes (UFRN), under the number CAAE 81973618.2.0000.5292 (date of
25
26 approval: April 17, 2018; reference number: CAAE 81973618.2.0000.5292) and was
27
28 registered in REBEC (Brazilian Registry of Clinical Trials) under number RBR-
29
30 94DX93. before enrollment of trial participants. Patients confidentiality will be
31
32 assured through data anonymization.
33
34
35
36
37
38
39

40 **REFERENCES**

- 41
42
43 1. Management of symptomatic vulvovaginal atrophy: 2013 position statement
44
45 of The North American Menopause Society. *Menopause* 2013;20(9):888–
46
47 902.
48
49
50 2. Portman DJ, Gass MLS. Vulvovaginal Atrophy Terminology Consensus
51
52 Conference Panel. Genitourinary syndrome of menopause: new terminology
53
54 for vulvovaginal atrophy from the International Society for the Study of
55
56 Women's Sexual Health and the North American Menopause Society.
57
58 *Maturitas* 2014;79(3):349–54.
59
60

- 1
2
3 3. Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause:
4 an overview of clinical manifestations, pathophysiology, etiology, evaluation,
5 and management. *Am J Obstet Gynecol* 2016;215:704-711.
6
7
- 8
9
10 4. Tzur T, Yohai D, Weintraub AY. The role of local estrogen therapy in the
11 management of pelvic floor disorders. *Climacteric* 2016;19:162-171.
12
- 13
14 5. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in
15 postmenopausal women. *Cochrane Database Syst Rev* 2016;8:CD001500.
16
- 17
18 6. Filippini M, Luvero D, Salvatore S, Pieralli A, Montera R, Plotti F, et al.
19 Efficacy of fractional CO2 laser treatment in postmenopausal women with
20 genitourinary syndrome. *Menopause*. 2019;1(27):000-000.
21
22
- 23
24 7. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al.
25 A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a
26 pilot study. *Climacteric*. 2014;17(4):363–369.
27
28
- 29
30 8. Athanasiou S, Pitsouni E, Falagas ME, Salvatore S, Grigoriadis T. CO 2 -
31 laser for the genitourinary syndrome of menopause. How many laser
32 sessions? *Maturitas*. 2017;104:24–28.
33
34
- 35
36 9. Gambacciani M, Levancini M. Vaginal erbium laser as second-generation
37 thermotherapy for the genitourinary syndrome of menopause. *Menopause*.
38 2017; 24(3):316–319.
39
40
- 41
42 10. Flint R, Cardozo L, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S.
43 Rationale and design for fractional microablative CO2 laser versus
44 photothermal non-ablative erbium:YAG laser for the management of
45 genitourinary syndrome of menopause: a non-inferiority, single-blind
46 randomized controlled trial. *Climacteric*. 2019;1–5.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 11. Vicariotto F, DE Seta F, Faoro V, et al. Dynamic
4
5 quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-
6
7 vaginal atrophy: 12-month efficacy and safety. *Minerva Ginecol* 2017;69:
8
9 342-349.
10
11
- 12 12. Casabona G, Presti C, Manzini M, et al. Fractional ablative radiofrequency:
13
14 a pilot study with twenty cases involving rejuvenation of the lower eyelid.
15
16 *Surg Cosmet Dermatol* 2014;6(1):50-5.
17
18
- 19 13. Kamilos MF, Borelli CL. New therapeutic option in genitourinary syndrome
20
21 of menopause: pilot study using microablative fractional radiofrequency.
22
23 *Einstein* 2017;(15):445-51.
24
25
- 26 14. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
27
28 SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
29
30 trials. *BMJ* 2013;346:e7586.
31
32
- 33 15. Schulz KF, Altman DG, Moher D. CONSORT 2010: updated guidelines for
34
35 reporting parallel group randomised trials. *Ann Intern Med* 2010;152:1–8.
36
37
- 38 16. Constantine GD, Simon JA, Pickar JH, et al; REJOICE Study Group. The
39
40 REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety
41
42 and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic
43
44 vulvar and vaginal atrophy. *Menopause* 2017;24(4):409-416.
45
46
- 47 17. Simon JA, Archer DF, Constantine GD, et al. A vaginal estradiol softgel
48
49 capsule, TX-004HR, has negligible to very low systemic absorption of
50
51 estradiol: efficacy and pharmacokinetic data review. *Maturitas* 2017;99:51-
52
53 58.
54
55
56
57
58
59
60

- 1
2
3 18. Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause:
4 Management Strategies for the Clinician. *Mayo Clin Proc* 2017;92(12):1842-
5 1849.
6
7
8
9
10 19. Bachmann GA, Notelovitz M, Kelly SJ, et al. Long-term non-hormonal
11 treatment of vaginal dryness. *Clin Pract Sexuality*. 1992;8:3 – 8.
12
13 20. Sokol ER, Karram MM. An assessment of the safety and efficacy of a
14 fractional CO2 laser system for the treatment of vulvovaginal atrophy.
15 *Menopause*. 2016;23(10):1102–1107.
16
17
18 21. Song S, Budden A, Short A, Nesbitt-Hawes E, Deans R, Abbott J. The
19 evidence for laser treatments to the vulvo-vagina: Making sure we do not
20 repeat past mistakes. *Aust N Z J Obstet Gynaecol*. 2017;58(2):148–162.
21
22
23 22. Salvatore S, Nappi RE, Parma M, et al. (2014). Sexual function after
24 fractional microablative CO2 laser in women with vulvovaginal atrophy.
25 *Climacteric*. 2014;18(2):219–225.
26
27
28 23. Thiel R, Dambros M, Palma PCR, Thiel M, Riccetto CLZ, Ramos MF.
29 [Translation into Portuguese, cross-national adaption and validation of the
30 Female Sexual Function Index]. *Rev Bras Ginecol Obstet*. 2008;30(10):504-
31 510. Portuguese
32
33
34 24. Hentschel H, Alberton DL, Capp E, Goldim JR, Passos EP. Validation of the
35 Female Sexual Function Index (FSFI) for portuguese language. *Rev. HCPA*
36 2007;27(1).
37
38
39 25. Davis SR. Understanding female sexual function. *Menopause*. 16. 2009;(3):425–
40 430. doi:10.1097/gme.0b013e31819c67a7.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 26. Ware J, Kosinski M, Keller SD. A 12-item short-form health survey:
4 construction of scales and preliminary tests of reliability and validity. *Med*
5 *Care*. 1996;34:220 – 33.
6
7
8
9
10 27. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic
11 vaginitis. *Am Fam Physician*. 2000;61(10):3090-6.
12
13
14 28. Sarmiento AC, Fernandes FS, Marconi C, et al. Impact of microablative
15 fractional radiofrequency on the vaginal health, microbiota, and cellularity o
16 postmenopausal women. *CLINICS*. 2020;75:1750.
17
18
19
20
21 29. Athanasiou S, Pitsouni E, Douskos A, Salvatore S, Loutradis D, Grigoriadis
22 T. Intravaginal energy-based devices and sexual health of female cancer
23 survivors: a systematic review and meta-analysis. *Lasers in Medical*
24 *Science*. 2019.
25
26
27
28
29
30 30. Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas ME, Athanasiou
31 S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual
32 function and orgasm of menopausal women: A systematic review and meta-
33 analysis of randomized controlled trials. *European Journal of Obstetrics &*
34 *Gynecology and Reproductive Biology*. 2018;229:45–56.
35
36
37
38
39
40
41
42 31. Jha S, Wyld L, Krishnaswamy PH. The impact of vaginal laser treatment for
43 genitourinary syndrome of the menopause in breast cancer survivors: a
44 systematic reiew and meta-analysis. *Clinical Breast Cancer*.
45 2019;19(4):556-562.
46
47
48
49
50
51 32. Sarmiento ACA, Lírio JF, Medeiros KS, et al. Physical methods for the
52 treatment of genitourinary syndrome of menopause: A systematic review.
53 *IJGO*. 2020;153(2):200-219.
54
55
56
57
58
59
60

1
2
3 **Authors' contributions:** ACAS, AKG were involved in drafting the study protocol.
4
5 KM and APFC were involved in statistical planning and drafting of the study protocol.
6
7 JCC and FSF was involved in drafting and revising the study protocol. AKG
8
9 developed the idea for this trial and was involved in drafting and revising the study
10
11 protocol. ACAS conceived and developed the idea for this trial, was involved in
12
13 drafting and revising the study protocol and was the principal investigator of this trial.
14
15 All authors are involved in data acquisition and approved the final version of the
16
17 manuscript.
18
19
20
21

22 **Conflict of interest statement:** The authors report no conflict of interest.
23

24 **Funding:** This work was supported by Brazilian CNPq (National Council for
25
26 Scientific and Technological Development). Grant number 436740/2018-4.
27

28 **Disclaimer:** These funding sources have no role in the design of this study and will
29
30 not have any role during its execution, analyses, interpretation of the data, or
31
32 decision to submit results.
33
34

35 **Data sharing statement:** All investigators will maintain full autonomy and
36
37 involvement in the design, conduct and reporting of the trial with everyone having
38
39 full access to the final data.
40
41

42 **Confidentiality:** The original documents and files will be kept at the trial sites for
43
44 15 years. The lead investigator is responsible for data and file storage. The lead
45
46 investigator is responsible for data and files storage for 15 years.
47
48

49 **Consent or assent:** All participants will be asked to sign an informed consent form
50
51 to join the trial. The form explicitly contains all stages of research.
52
53

54 **Ethics approval:** The trial was approved by the local Division Ethics Committee
55
56 (date of approval: April 17, 2018; reference number: 81973618.2.0000.5292) and
57
58
59
60

1
2
3 registered in the Brazilian Clinical Trials Registry - ReBec: (number registry RBR-
4
5 94DX93).
6
7
8
9
10
11

12 **Figure legend:**
13

14 **Figure 1. CONSORT 2010 Flow Diagram**
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. CONSORT 2010 Flow Diagram

Figure 1. CONSORT 2010 Flow Diagram

189x222mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	01
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	01
	2b	All items from the World Health Organization Trial Registration Data Set	01
Protocol version	3	Date and version identifier	01
Funding	4	Sources and types of financial, material, and other support	01
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	01
	5b	Name and contact information for the trial sponsor	X
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	X
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	X

1	Introduction			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	04-05
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	05
7				
8	Objectives	7	Specific objectives or hypotheses	06
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	06
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	06
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	07
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	07-08
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	07
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	07-08
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	08
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	08-10
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
35			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	11-12
39			participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	12
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	13
5				

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	13
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	13
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	13
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	13
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	13
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13-14
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13-14
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	14
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	14
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	X
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	X
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	X
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	22
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	22
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	X
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	22
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	22
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	22
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	X
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	X
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	X
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	X
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	✓
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	X
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.